Global Campaign for Microbicides

Home

Home » About Microbicides » Microbicide Candidates

Microbicide Candidates

On this page, you will find:

There are 12 microbicide products currently in clinical trials globally. Multiple candidate microbicides with different target pathogens and mechanisms of action must be tested simultaneously. This increases the probability and speed of finding a successful microbicide, and with time will lead to a variety of products with different attributes for different users.

Phase

Candidate Name

Sponsor*

Sites by Country

3

PRO 2000/5 gel

Indevus, MRC, DFID (Funder)

South Africa, Tanzania, Uganda, Zambia

2B

Tenofovir gel

CAPRISA, USAID, LIFElab, Gilead, FHI, CONRAD

South Africa

2/2B

PRO 2000/5 gel (P)

and BufferGel®

NIAID, Indevus, ReProtect

Malawi, South Africa,  United States, Zambia, Zimbabwe

1

Dapivirine (TMC120) gel

IPM

Belgium

Ethanol in

Emollient Gel

NIAID

Kenya

Tenofovir/PMPA gel

CONRAD, IPM/USAID

Dominican Republic, United States

UC-781 gel

NIAID, CONRAD

United States

UC-781 gel

UCLA, NIAID, CONRAD

United States

UC-781 gel

CDC, Thailand Ministry of Health, CONRAD

Thailand

UC-781

CONRAD

United States

UC-781

CONRAD, CDC, Emory University

United States

VivaGel™

(SPL7013 gel)†

DAIDS/NIAID, NICHD, Starpharma

Puerto Rico, United States

VivaGel™

(SPL7013 gel)

NIH/NIAID/DMID, Starpharma

Kenya, United States

Tenofovir gel

NIAID

United States

N/A

Placebo ring**

IPM

Kenya, South Africa, Tanzania

 

©Alliance for Microbicide Development 2008

For modifications, please contact Stephanie Tillman, email stillman@microbicide.org, tel. +301-587-3302.

 

Definition of acronyms used in this table: Mechanism of Action (MoA), Entry/Fusion Inhibitor (EFI),Replication Inhibitor (RI), and Vaginal Defense Enhancer (VDE)

 

*The Alliance uses the term “sponsor” as defined by the International Conference on Harmonisation (Guideline for Good Clinical Practice, 1996) as follows: “An individual, company, institution, or organization which takes responsibility for the initiation, management, and/or financing of a clinical trial.”

 † This trial has been paused pending a protocol amendment.

‡ ATN 062, “Tell Juliana,” is an observational study taking place in parallel to MTN 004. Please visit the MRDD for further information on this ancillary study.

**This device is intended for use with a microbicide.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 




Candidates most advanced in Clinical Trials

The following are descriptions of the four candidate microbicides entering advanced trials. For more information on these and other candidate products, please visit the Alliance for Microbicide Development’s website www.microbicide.org or check out Factsheet #13: Trials Watch in one of our different languages US English - English - French - Spanish - Russian

BufferGel is an acid buffer that keeps the vagina acidic even in the presence of semen and creates a physical barrier that stops or slows down the passage of pathogens into the vaginal and cervical walls. It is expected to be contraceptive and may protect against HIV, HPV, HSV, chlamydia and gonorrhea. Carbopol 974, the major nonaqueous component of BufferGel, is commonly used as a gelling or tableting agent.

PRO 2000 (napthalene sulphonate polymer) is an entry and fusion inhibitor that binds to viruses and bacteria to prevent them from binding to and infecting healthy cells. Its contraceptive efficacy is expected to be dose dependent. It may protect against HIV, gonorrhoea and HSV.